$0.38
0.90%
Nasdaq, Oct 21, 03:15 pm EDT. Closed.
ISIN
US62818Q1040
Symbol
MBIO

Mustang Bio, Inc. Stock price

$0.38
-0.17 30.38% 1M
-0.33 46.53% 6M
-0.60 60.97% YTD
-1.17 75.30% 1Y
-83.62 99.54% 3Y
-1,657.12 99.98% 5Y
-7,349.62 99.99% 10Y
-7,349.62 99.99% 20Y
Nasdaq, Closing price Wed, Oct 21 2026
+0.00 0.90%
ISIN
US62818Q1040
Symbol
MBIO
Industry

Is Mustang Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,102 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.9m
Enterprise Value
$-12.3m
Net debt
positive
Cash
$15.2m
Shares outstanding
7.6m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
2.7 | 2.7
P/B
0.4
Financial Health
Equity Ratio
54.2%
Return on Equity
-20.2%
ROCE
-45.8%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$90.0k | -
SBC as % of FCF
-
SBC Growth 1Y
12.5%
Share Count Growth 1Y
73.1%
Shareholder Yield
-73.1%
Financials
Revenue | estimate
$0.0 | -
EBITDA
$-3.5m
EBIT
$-3.5m
Net Income
$-3.0m
Free Cash Flow | ex SBC
$-4.5m | $-4.6m
Growth
Revenue | estimate
- | -
EBITDA
-37.0%
EBIT
-36.9%
Net Income
7.6%
Free Cash Flow
30.4%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.5
FCF per Share
$-0.6
Short interest
0.8%
Employees
4
Rev per Employee
$0.0

Mustang Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Mustang Bio, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Mustang Bio, Inc. forecast:

Buy
86%
Hold
14%

Mustang Bio, Inc. Events

Upcoming Event
NOV
5
Q3 2026 Earnings Call
in 14 days

Financial data from Mustang Bio, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.77 3.77
19% 19%
-
- Research and Development Expense 2.25 2.25
378% 378%
-
-3.52 -3.52
37% 37%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.52 -3.52
37% 37%
-
Net Profit -3.03 -3.03
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Mustang Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mustang Bio, Inc. Stock News

Neutral
GlobeNewsWire
●
4 months ago
VANCOUVER, British Columbia, June 09, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), (the “Company” or “MindBio”), a biotechnology company commercializing AI-driven voice analytics for intoxication and fatigue detection, is pleased to announce the Company has completed the manufacture of and delivered its first prototype Edge AI Intoxication Detec...
Neutral
GlobeNewsWire
●
5 months ago
Disseminated on behalf of  MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)  and may include paid advertising. NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specia...
Neutral
GlobeNewsWire
●
5 months ago
This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising
More Mustang Bio, Inc. News

Company Profile

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Head office United States
CEO Dr. Litchman
Employees 4
Founded 2015
Website www.mustangbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today